The RNAi therapeutic vutrisiran met its primary and secondary endpoints in the HELIOS-A phase 3 study of patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Medscape Medical News

The RNAi therapeutic vutrisiran met its primary and secondary endpoints in the HELIOS-A phase 3 study of patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Medscape Medical News